Dementia Associated with Alzheimer’s Disease– Pipeline Review, 2019

Alzheimer’s disease is considered the third leading cause of death among the geriatric patient population in the U.S. after cancer and heart disease. According to 2019 Alzheimer’s Disease Facts and Figures by Alzheimer’s Association it is estimated that currently among 5.8 million Americans living with Alzheimer’s dementia, 81% of them comprises of the older population of age 75 years. Dementia associated with Alzheimer’s disease is characterized by behavioral, memory and thinking symptoms such as agitation and suspiciousness that destroys the person’s ability to carry out general daily which further necessitates the assistance with daily living around the clock.

Brain imaging techniques and blood test are used for the identification of high-level of accumulation of protein beta-amyloid, a hallmark pathology of Alzheimer’s disease and carrying out a neurological and physical examination to check any behavioral changes due to dementia are the some of the diagnostic approaches for dementia due to Alzheimer’s disease. Aging, frequency of difference in APOE gene, cardiovascular disease, and traumatic brain injury are some of the risk factors associated with Alzheimer’s dementia.

Currently, there is no effective pharmacological treatment that stops the damage of neurons causing Alzheimer’s dementia. Some of the medications such as rivastigmine, galantamine, donepezil, memantine, memantine combined with donepezil are used temporally to improve the symptoms associated with Alzheimer’s dementia. Biomarker tests can be used for the identification of Alzheimer’s dementia in the early stage, providing patients with an option of effective treatment therapy.

To know how our report can help streamline your business, Speak to Analyst

Currently, Otsuka Pharmaceutical Co., Ltd. has sponsored the clinical trial study to evaluate the safety of brexpiprazole after a 14-week treatment regimen for agitation associated with dementia of the Alzheimer's type patients, who have completed a double-blind trial. This study is in phase 3 of the clinical tiral, which aims to investigate the efficacy of brexpiprazole. Metabolic Therapy Inc. has sponsored the study focusing on quantitative analysis of EEG scan device for monitoring of the neurological functioning during the onset and progression of cognitive decline in preclinical Alzheimer's patients in collaboration with the Institute of Asian American Adult Development.

Report Description

The report on ‘Dementia Associated with Alzheimer’s Disease– Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for deep vein thrombosis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Dementia associated with Alzheimer’s disease.

The report on ‘Dementia associated with Alzheimer’s Disease– Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights about the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products fordementia associated with Alzheimer’s disease


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players about R&D for Dementia associated with Alzheimer’s disease


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary